Blood Reviews
Volume 23, Issue 2 , Pages 67-78 , March 2009

Cardiovascular disease and heritability of the prothrombotic state

References 

  1. Badimon L, Badimon JJ, Vilahur G, Segales E, Llorente V. Pathogenesis of the acute coronary syndromes and therapeutic implications. Pathophysiol Haemost Thromb. 2002;32(5–6):225–231
  2. Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol Haemost Thromb. 2003;33(5–6):375–381
  3. Norris LA. Blood coagulation. Best Pract Res Clin Obstet Gynaecol. 2003;17(3):369–383
  4. Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost. 2002;88(2):186–193
  5. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol. 2002;22(9):1381–1389
  6. Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest. 1979;64(5):1393–1401
  7. Greenberg CS, Lai TS, Ariëns RAS, Weisel JW, Grant PJ. Biology and disorders of fibrinogen and factor XIII. In:  Handin RI,  Lux SE,  Stossel TP editor. Blood-Principles and Practice of Hematology. Lippincott Williams & Wilkins; 2001;p. 1225–1248
  8. Litvinov RI, Gorkun OV, Galanakis DK, Yakovlev S, Medved L, Shuman H, et al. Polymerization of fibrin: direct observation and quantification of individual B:b knob–hole interactions. Blood. 2007;109(1):130–138
  9. Weisel JW. Fibrinogen and fibrin. Adv Protein Chem. 2005;70:247–299
  10. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol. 2005;129(3):307–321
  11. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994;90(1):61–68
  12. Gulba DC, Barthels M, Reil GH, Lichtlen PR. Thrombin/antithrombin-III complex level as early predictor of reocclusion after successful thrombolysis. Lancet. 1988;2(8602):97
  13. Bounameaux H, Cirafici P, de Moerloose P, et al. Measurement of D-dimer in plasma as diagnostic aid in suspected pulmonary embolism. Lancet. 1991;337(8735):196–200
  14. van der Poll, Buller HR, ten Cate H, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. New Engl J Med. 1990;322(23):1622–1627
  15. Ariëns RA, de Lange M, Snieder H, Boothby M, Spector TD, Grant PJ. Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. Lancet. 2002;359(9307):667–671
  16. Rosendaal FR, Bovill EG. Heritability of clotting factors and the revival of the prothrombotic state. Lancet. 2002;359(9307):638–639
  17. Vossen CY, Hasstedt SJ, Rosendaal FR, et al. Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C-deficient family. J Thromb Haemost. 2004;2(2):242–247
  18. Anderson TJ. Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Fail Rev. 2003;8(1):71–86
  19. Blann AD. Assessment of endothelial dysfunction: focus on atherothrombotic disease. Pathophysiol Haemost Thromb. 2003;33(5–6):256–261
  20. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004;109(23 Suppl 1):III27–III32
  21. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2005;85(1):1–31
  22. Tousoulis D, Davies G, Stefanadis C, Toutouzas P, Ambrose JA. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart. 2003;89(9):993–997
  23. Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation. 1997;96(2):396–399
  24. Miller DL, Yaron R, Yellin MJ. CD40L–CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression. J Leukoc Biol. 1998;63(3):373–379
  25. Fukudome K, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem. 1994;269(42):26486–26491
  26. Archipoff G, Beretz A, Freyssinet JM, Klein-Soyer C, Brisson C, Cazenave JP. Heterogeneous regulation of constitutive thrombomodulin or inducible tissue-factor activities on the surface of human saphenous-vein endothelial cells in culture following stimulation by interleukin-1, tumour necrosis factor, thrombin or phorbol ester. Biochem J. 1991;273(Pt 3):679–684
  27. Esmon CT. The impact of the inflammatory response on coagulation. Thromb Res. 2004;114(5–6):321–327
  28. Rosenson RS, Koenig W. Utility of inflammatory markers in the management of coronary artery disease. Am J Cardiol. 2003;92(1A):10i–18i
  29. Sturn DH, Kaneider NC, Feistritzer C, Djanani A, Fukudome K, Wiedermann CJ. Expression and function of the endothelial protein C receptor in human neutrophils. Blood. 2003;102(4):1499–1505
  30. Conway EM, Van de WM, Pollefeyt S, et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med. 2002;196(5):565–577
  31. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res. 2004;61(3):498–511
  32. Danesh J, Whincup P, Walker M, et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation. 2001;103(19):2323–2327
  33. Lowe GD, Yarnell JW, Rumley A, Bainton D, Sweetnam PM. C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis?. Arterioscler Thromb Vasc Biol. 2001;21(4):603–610
  34. Robson SC, Shephard EG, Kirsch RE. Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1 beta, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol. 1994;86(2):322–326
  35. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. New Engl J Med. 1994;330(15):1041–1046
  36. de Lange M, Snieder H, Ariëns RA, Spector TD, Grant PJ. The genetics of haemostasis: a twin study. Lancet. 2001;357(9250):101–105
  37. Mills JD, Ariëns RA, Mansfield MW, Grant PJ. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation. 2002;106(15):1938–1942
  38. Dunn EJ, Ariëns RA, de Lange M, et al. Genetics of fibrin clot structure: a twin study. Blood. 2004;103(5):1735–1740
  39. Hammar N, Kaprio J, Hagstrom U, Alfredsson L, Koskenvuo M, Hammar T. Migration and mortality: a 20 year follow up of Finnish twin pairs with migrant co-twins in Sweden. J Epidemiol Community Health. 2002;56(5):362–366
  40. Suefuji H, Ogawa H, Yasue H, et al. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J. 1997;134(2 Pt 1):253–259
  41. Soejima H, Ogawa H, Yasue H, et al. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation. 1999;99(22):2908–2913
  42. Ott I, Koch W, von Beckerath N, et al. Tissue factor promotor polymorphism −603 A/G is associated with myocardial infarction. Atherosclerosis. 2004;177(1):189–191
  43. Reny JL, Laurendeau I, Fontana P, et al. The TF-603A/G gene promoter polymorphism and circulating monocyte tissue factor gene expression in healthy volunteers. Thromb Haemost. 2004;91(2):248–254
  44. Arnaud E, Barbalat V, Nicaud V, Cambien F, Evans A, Morrison C, et al. Polymorphisms in the 5′ regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism: the ECTIM and PATHROS studies. Etude Cas-Temoins de l’Infarctus du Myocarde. Paris Thrombosis case–control study. Arterioscler Thromb Vasc Biol. 2000;20(3):892–898
  45. Hedner U. General haemostatic agents – fact or fiction?. Pathophysiol Haemost Thromb. 2002;32(Suppl 1):33–36
  46. Cooper JA, Miller GJ, Bauer KA, et al. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation. 2000;102(23):2816–2822
  47. Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis. 1991;91(3):191–205
  48. Heinrich J, Balleisen L, Schulte H, Assmann G, van de LJ. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb. 1994;14(1):54–59
  49. Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery study. Arterioscler Thromb Vasc Biol. 1997;17(11):3321–3325
  50. Voetsch B, Loscalzo J. Genetic determinants of arterial thrombosis. Arterioscler Thromb Vasc Biol. 2004;24(2):216–229
  51. Iacoviello L, Di Castelnuovo A, de Knijff P, et al. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. New Engl J Med. 1998;338(2):79–85
  52. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1997;96(4):1102–1108
  53. Doggen CJ, Manger CV, Bertina RM, Reitsma PH, Vandenbroucke JP, et al. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men. Thromb Haemost. 1998;80(2):281–285
  54. van der Krabben, Rosendaal FR, van der Bom JG, Doggen CJ. Polymorphisms in coagulation factors and the risk of recurrent cardiovascular events in men after a first myocardial infarction. J Thromb Haemost. 2008;6(5):720–725
  55. Eriksson-Berg M, Deguchi H, Hawe E, et al. Influence of factor VII gene polymorphisms and environmental factors on plasma coagulation factor VII concentrations in middle-aged women with and without manifest coronary heart disease. Thromb Haemost. 2005;93(2):351–358
  56. Marchetti G, Patracchini P, Papacchini M, Ferrati M, Bernardi F. A polymorphism in the 5′ region of coagulation factor VII gene (F7) caused by an inserted decanucleotide. Hum Genet. 1993;90(5):575–576
  57. ’t Hooft FM, Silveira A, Tornvall P, et al. Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration. Blood. 1999;93(10):3432–3441
  58. Bernardi F, Arcieri P, Bertina RM, et al. Contribution of factor VII genotype to activated FVII levels Differences in genotype frequencies between northern and southern European populations. Arterioscler Thromb Vasc Biol. 1997;17(11):2548–2553
  59. Girelli D, Russo C, Ferraresi P, et al. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. New Engl J Med. 2000;343(11):774–780
  60. Carew JA, Basso F, Miller GJ, et al. A functional haplotype in the 5′ flanking region of the factor VII gene is associated with an increased risk of coronary heart disease. J Thromb Haemost. 2003;1(10):2179–2185
  61. Bozzini C, Girelli D, Bernardi F, et al. Influence of polymorphisms in the factor VII gene promoter on activated factor VII levels and on the risk of myocardial infarction in advanced coronary atherosclerosis. Thromb Haemost. 2004;92(3):541–549
  62. Campo G, Valgimigli M, Ferraresi P, et al. Tissue factor and coagulation factor VII levels during acute myocardial infarction: association with genotype and adverse events. Arterioscler Thromb Vasc Biol. 2006;26(12):2800–2806
  63. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279(18):1477–1482
  64. Iacoviello L, Vischetti M, Zito F, Benedetta DM. Genes encoding fibrinogen and cardiovascular risk. Hypertension. 2001;38(5):1199–1203
  65. Green FR. Fibrinogen polymorphisms and atherothrombotic disease. Ann NY Acad Sci. 2001;936:549–559
  66. Grant PJ. The genetics of atherothrombotic disorders: a clinician’s view. J Thromb Haemost. 2003;1(7):1381–1390
  67. Reed GL, Houng AK. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism. Circulation. 1999;99(2):299–304
  68. Anwar R, Gallivan L, Edmonds SD, Markham AF. Genotype/phenotype correlations for coagulation factor XIII: specific normal polymorphisms are associated with high or low factor XIII specific activity. Blood. 1999;93(3):897–905
  69. Ariëns RA, Lai TS, Weisel JW, Greenberg CS, Grant PJ. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood. 2002;100(3):743–754
  70. Lowe GD, Yarnell JW, Sweetnam PM, Rumley A, Thomas HF, Elwood PC. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly study. Thromb Haemost. 1998;79(1):129–133
  71. Cushman M, Lemaitre RN, Kuller LH, et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health study. Arterioscler Thromb Vasc Biol. 1999;19(3):493–498
  72. Saigo M, Abe S, Ogawa M, et al. Imbalance of plasminogen activator inhibitor-I/tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction. Thromb Haemost. 2001;86(5):1197–1203
  73. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT study group European concerted action on thrombosis and disabilities. Circulation. 1996;94(9):2057–2063
  74. Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2001;21(4):611–617
  75. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2(8549):3–9
  76. Lowe GD, Danesh J, Lewington S, et al. Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis. Eur Heart J. 2004;25(3):252–259
  77. Nordenhem A, Leander K, Hallqvist J, de Faire U, Sten-Linder M, Wiman B. The complex between tPA and PAI-1: risk factor for myocardial infarction as studied in the SHEEP project. Thromb Res. 2005;116(3):223–232
  78. Nordenhem A, Wiman B. Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes. Scand J Clin Lab Invest. 1998;58(6):475–483
  79. Nordt TK, Lohrmann J, Bode C. Regulation of PAI-1 expression by genetic polymorphisms Impact on atherogenesis. Thromb Res. 2001;103(Suppl 1):S1–S5
  80. Zhan M, Zhou Y, Han ZC. No association of the plasminogen activator inhibitor-1 promoter 4G/5G polymorphism with inhibitor level during basal transcription in vitro. Int J Hematol. 2004;79(4):400–404
  81. Hoekstra T, Geleijnse JM, Schouten EG, Kluft C. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost. 2004;91(5):861–872
  82. Humphries SE, Lane A, Dawson S, Green FR. The study of gene–environment interactions that influence thrombosis and fibrinolysis Genetic variation at the loci for factor VII and plasminogen activator inhibitor-1. Arch Pathol Lab Med. 1992;116(12):1322–1329
  83. Iacoviello L, Burzotta F, Di Castelnuovo A, Zito F, Marchioli R, Donati MB. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb Haemost. 1998;80(6):1029–1030
  84. Ludwig M, Wohn KD, Schleuning WD, Olek K. Allelic dimorphism in the human tissue-type plasminogen activator (TPA) gene as a result of an Alu insertion/deletion event. Hum Genet. 1992;88(4):388–392
  85. van der Bom JG, de Knijff P, Haverkate F, et al. Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam study. Circulation. 1997;95(12):2623–2627
  86. Ridker PM, Baker MT, Hennekens CH, Stampfer MJ, Vaughan DE. Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risks of myocardial infarction among middle-aged men. Arterioscler Thromb Vasc Biol. 1997;17(9):1687–1690
  87. Ladenvall P, Johansson L, Jansson JH, et al. Tissue-type plasminogen activator −7351C/T enhancer polymorphism is associated with a first myocardial infarction. Thromb Haemost. 2002;87(1):105–109
  88. Ladenvall P, Nilsson S, Jood K, Rosengren A, Blomstrand C, Jern C. Genetic variation at the human tissue-type plasminogen activator (tPA) locus: haplotypes and analysis of association to plasma levels of tPA. Eur J Hum Genet. 2003;11(8):603–610
  89. Fatah K, Silveira A, Tornvall P, Karpe F, Blomback M, Hamsten A. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost. 1996;76(4):535–540
  90. Collet JP, Park D, Lesty C, et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol. 2000;20(5):1354–1361
  91. Ajjan R, Lim BC, Standeven KF, et al. Common variation in the C-terminal region of the fibrinogen beta-chain: effects on fibrin structure, fibrinolysis and clot rigidity. Blood. 2008;111(2):643–650
  92. Blombäck B. Fibrinogen structure, activation, polymerization and fibrin gel structure. Thromb Res. 1994;75(3):327–328
  93. Standeven KF, Grant PJ, Carter AM, Scheiner T, Weisel JW, Ariëns RA. Functional analysis of the fibrinogen Aa Thr312Ala polymorphism: effects on fibrin structure and function. Circulation. 2003;107(18):2326–2330
  94. Carter AM, Catto AJ, Grant PJ. Association of the alpha-fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation. 1999;99(18):2423–2426
  95. Carter AM, Catto AJ, Kohler HP, Ariëns RA, Stickland MH, Grant PJ. alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism. Blood. 2000;96(3):1177–1179
  96. Suntharalingam J, Goldsmith K, van Marion V, et al. Fibrinogen AalphaThr312Ala polymorphism is associated with Chronic Thromboembolic Pulmonary Hypertension. Eur Respir J. 2008;31(4):736–741
  97. Rasmussen-Torvik LJ, Cushman M, Tsai MY, Zhang Y, Heckbert SR, Rosamond WD, et al. The association of alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism in the LITE study. Thromb Res. 2007;121(1):1–7
  98. Behague I, Poirier O, Nicaud V, et al. Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM study. Etude Cas-Temoins sur l’Infarctus du Myocarde. Circulation. 1996;93(3):440–449
  99. French JK, Van de Water NS, Sutton TM, et al. Potential thrombophilic mutations/polymorphisms in patients with no flow-limiting stenosis after myocardial infarction. Am Heart J. 2003;145(1):118–124
  100. Carter AM, Catto AJ, Bamford JM, Grant PJ. Gender-specific associations of the fibrinogen B beta 448 polymorphism, fibrinogen levels, and acute cerebrovascular disease. Arterioscler Thromb Vasc Biol. 1997;17(3):589–594
  101. Scrutton MC, Ross-Murphy SB, Bennett GM, Stirling Y, Meade TW. Changes in clot deformability – a possible explanation for the epidemiological association between plasma fibrinogen concentration and myocardial infarction. Blood Coagul Fibrinolysis. 1994;5(5):719–723
  102. Standeven KF, Ariëns RA, Grant PJ. The molecular physiology and pathology of fibrin structure/function. Blood Rev. 2005;19(5):275–288
  103. Kobbervig C, Williams E. FXIII polymorphisms, fibrin clot structure and thrombotic risk. Biophys Chem. 2004;112(2–3):223–228
  104. Shafey M, Anderson JL, Scarvelis D, Doucette SP, Gagnon F, Wells PS. Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysis. Thromb Haemost. 2007;97(4):635–641
  105. Ariëns RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood. 2000;96(3):988–995
  106. Bereczky Z, Balogh E, Katona E, et al. Decreased factor XIII levels in factor XIII A subunit Leu34 homozygous patients with coronary artery disease. Thromb Res. 2008;121(4):469–476
  107. Trumbo TA, Maurer MC. Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation. J Biol Chem. 2000;275(27):20627–20631
  108. Marin F, Gonzalez-Conejero R, Lee KW, et al. A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction. J Am Coll Cardiol. 2005;45(1):25–29
  109. Gonzalez-Conejero R, Fernandez-Cadenas I, Iniesta JA, et al. Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke. 2006;37(9):2288–2293
  110. Kohler HP, Mansfield MW, Clark PS, Grant PJ. Interaction between insulin resistance and factor XIII Val34Leu in patients with coronary artery disease. Thromb Haemost. 1999;82(3):1202–1203
  111. Boekholdt SM, Sandhu MS, Wareham NJ, Luben R, Reitsma PH, Khaw KT. Fibrinogen plasma levels modify the association between the factor XIII Val34Leu variant and risk of coronary artery disease: the EPIC-Norfolk prospective population study. J Thromb Haemost. 2006;4(10):2204–2209
  112. Bereczky Z, Balogh E, Katona E, et al. Modulation of the risk of coronary sclerosis/myocardial infarction by the interaction between factor XIII subunit A Val34Leu polymorphism and fibrinogen concentration in the high risk Hungarian population. Thromb Res. 2007;120(4):567–573
  113. Lim BC, Ariens RA, Carter AM, Weisel JW, Grant PJ. Genetic regulation of fibrin structure and function: complex gene–environment interactions may modulate vascular risk. Lancet. 2003;361(9367):1424–1431
  114. Wells PS, Anderson JL, Scarvelis DK, Doucette SP, Gagnon F. Factor XIII Val34Leu variant is protective against venous thromboembolism: a HuGE review and meta-analysis. Am J Epidemiol. 2006;164(2):101–109
  115. Pieters M, Covic N, van der Westhuizen FH, et al. Glycaemic control improves fibrin network characteristics in type 2 diabetes – a purified fibrinogen model. Thromb Haemost. 2008;99(4):691–700
  116. Jörneskog G, Egberg N, Fagrell B, et al. Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia. 1996;39(12):1519–1523
  117. Cubbon RM, Wheatcroft SB, Grant PJ, et al. Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003. Eur Heart J. 2007;28(5):540–545
  118. Sambola A, Osende J, Hathcock J, et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation. 2003;107(7):973–977
  119. Meade TW, North WR, Chakrabarti R, et al. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet. 1980;1(8177):1050–1054
  120. Hammer MR, John PN, Flynn MD, Bellingham AJ, Leslie RD. Glycated fibrinogen: a new index of short-term diabetic control. Ann Clin Biochem. 1989;26(Pt 1):58–62
  121. Dunn EJ, Ariëns RA. Fibrinogen and fibrin clot structure in diabetes. Herz. 2004;29(5):470–479
  122. Dunn EJ, Ariëns RA, Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologia. 2005;48(6):1198–1206
  123. Dunn EJ, Philippou H, Ariëns RA, Grant PJ. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia. 2006;49(5):1071–1080
  124. Pieters M, Covic N, Loots du T, et al. The effect of glycaemic control on fibrin network structure of type 2 diabetic subjects. Thromb Haemost. 2006;96(5):623–629
  125. Mansfield MW, Stickland MH, Grant PJ. PAI-1 concentrations in first-degree relatives of patients with non-insulin-dependent diabetes: metabolic and genetic associations. Thromb Haemost. 1997;77(2):357–361
  126. Carvalho de Sousa J, Bruckert E, Giral P, et al. Coagulation factor VII and plasma triglycerides Decreased catabolism as a possible mechanism of factor VII hyperactivity. Haemostasis. 1989;19(3):125–130
  127. Simpson HC, Mann JI, Meade TW, Chakrabarti R, Stirling Y, Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet. 1983;1(8328):786–790
  128. Iso H, Shimamoto T, Sato S, Koike K, Iida M, Komachi Y. Passive smoking and plasma fibrinogen concentrations. Am J Epidemiol. 1996;144(12):1151–1154
  129. Ariëns RA, Kohler HP, Mansfield MW, Grant PJ. Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals Relation to sex, age, smoking, and hypertension. Arterioscler Thromb Vasc Biol. 1999;19(8):2012–2016
  130. Mansfield MW, Kohler HP, Ariëns RA, McCormack LJ, Grant PJ. Circulating levels of coagulation factor XIII in subjects with type 2 diabetes and in their first-degree relatives. Diabetes Care. 2000;23(5):703–705
  131. Sasaki A, Kurisu A, Ohno M, Ikeda Y. Overweight/obesity, smoking, and heavy alcohol consumption are important determinants of plasma PAI-1 levels in healthy men. Am J Med Sci. 2001;322(1):19–23
  132. Yarnell JW, Sweetnam PM, Rumley A, Lowe GD. Lifestyle and hemostatic risk factors for ischemic heart disease: the Caerphilly study. Arterioscler Thromb Vasc Biol. 2000;20(1):271–279
  133. Dunstan DW, Mori TA, Puddey IB, et al. A randomised, controlled study of the effects of aerobic exercise and dietary fish on coagulation and fibrinolytic factors in type 2 diabetics. Thromb Haemost. 1999;81(3):367–372
  134. Peetz D, Victor A, Adams P, et al. Genetic and environmental influences on the fibrinolytic system: a twin study. Thromb Haemost. 2004;92(2):344–351
  135. De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest. 2002;25(10):899–904
  136. Lee KW, Lip GY. Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. Arch Intern Med. 2003;163(19):2368–2392
  137. de Gaetano G, Di Castelnuovo A, Donati MB, Iacoviello L. The mediterranean lecture: wine and thrombosis – from epidemiology to physiology and back. Pathophysiol Haemost Thromb. 2003;33(5–6):466–471
  138. de Maat MP. Effects of diet, drugs, and genes on plasma fibrinogen levels. Ann NY Acad Sci. 2001;936:509–521
  139. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004;24(11):1980–1987
  140. Bjornsson TD, Schneider DE, Berger H. Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharmacol Exp Ther. 1989;250(1):154–161
  141. Henschen-Edman AH. Fibrinogen non-inherited heterogeneity and its relationship to function in health and disease. Ann NY Acad Sci. 2001;936:580–593
  142. He S, Blombäck M, Yoo G, Sinha R, Henschen-Edman AH. Modified clotting properties of fibrinogen in the presence of acetylsalicylic acid in a purified system. Ann NY Acad Sci. 2001;936:531–535
  143. Undas A, Sydor WJ, Brummel K, Musial J, Mann KG, Szczeklik A. Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism. Circulation. 2003;107(1):17–20
  144. Mazoyer E, Ripoll L, Boisseau MR, Drouet L. How does ticlopidine treatment lower plasma fibrinogen?. Thromb Res. 1994;75(3):361–370
  145. Woodward M, Lowe GD, Francis LM, Rumley A, Cobbe SM. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. J Thromb Haemost. 2004;2(11):1934–1940
  146. Schmidt-Ott KM, Kagiyama S, Phillips MI. The multiple actions of angiotensin II in atherosclerosis. Regul Pept. 2000;93(1–3):65–77
  147. Rosenson RS. Modulating atherosclerosis through inhibition or blockade of angiotensin. Clin Cardiol. 2003;26(7):305–311
  148. Cooper ME. The role of the renin–angiotensin–aldosterone system in diabetes and its vascular complications. Am J Hypertens. 2004;17(11 Pt 2):16S–20S
  149. Fogari R, Zoppi A, Lazzari P, et al. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol. 1998;32(4):616–620
  150. Makris TK, Stavroulakis GA, Krespi PG, et al. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am J Hypertens. 2000;13(7):783–788
  151. Makris TK, Stavroulakis G, Papadopoulos DP, et al. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan. Drugs Exp Clin Res. 2004;30(3):125–132
  152. Fogari R, Mugellini A, Zoppi A, et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens. 2002;15(4 Pt 1):316–320
  153. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost. 2003;89(4):601–609
  154. Gotto AM. Statins, cardiovascular disease, and drug safety. Am J Cardiol. 2006;97(8A):3C–5C
  155. Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol. 2002;22(9):1452–1458
  156. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol. 2003;23(5):769–775
  157. Hakamada-Taguchi R, Uehara Y, et al. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res. 2003;93(10):948–956
  158. Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis. 2004;173(1):1–12
  159. Juhan-Vague I, Valadier J, Alessi MC, et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost. 1987;57(1):67–72
  160. Porreca E, Di Febbo C, Amore C, et al. Effect of lipid-lowering treatment on factor VII profile in hyperlipidemic patients. Thromb Haemost. 2000;84(5):789–793
  161. Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation. 2001;103(18):2248–2253
  162. Eto M, Kozai T, Cosentino F, Joch H, Luscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation. 2002;105(15):1756–1759
  163. Tekin A, Tekin G, Guzelsoy D, et al. Effects of atorvastatin (10mg) on hemostatic and inflammatory parameters in hyperlipidemic patients with angiographically proven coronary artery disease. Am J Cardiol. 2004;94(2):206–209
  164. Masamura K, Oida K, Kanehara H, et al. Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol. 2003;23(3):512–517
  165. Neve BP, Corseaux D, Chinetti G, et al. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation. 2001;103(2):207–212
  166. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin. 2002;18(5):269–276
  167. Kockx M, Gervois PP, Poulain P, et al. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. Blood. 1999;93(9):2991–2998
  168. Okopien B, Cwalina L, Lebek M, et al. Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia. Int J Clin Pharmacol Ther. 2001;39(12):551–557
  169. Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 2003;29(4 Pt 2):6S44–52.
  170. Charles MA, Morange P, Eschwege E, Andre P, Vague P, Juhan-Vague I. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study Biguanides and the Prevention of the Risk of Obesity. Diabetes Care. 1998;21(11):1967–1972
  171. Standeven KF, Ariëns RA, Whitaker P, Ashcroft AE, Weisel JW, Grant PJ. The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes. 2002;51(1):189–197
  172. Dhall DP, Nair CH. Effects of gliclazide on fibrin network. J Diabetes Complication. 1994;8(4):231–234
  173. UK Prospective Diabetes Study (UKPDS) Group . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–865
  174. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New Engl J Med. 2007;356(24):2457–2471
  175. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–1289
  176. Staels B. PPARgamma and atherosclerosis. Curr Med Res Opin. 2005;21(Suppl 1):S13–S20
  177. Chinetti G, Lestavel S, Bocher V, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med. 2001;7(1):53–58
  178. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106(6):679–684
  179. Li D, Chen K, Sinha N, Zhang X, et al. The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc Res. 2005;65(4):907–912
  180. Derosa G, Cicero AF, Gaddi A, et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract. 2005;69(1):5–13
  181. Allahtavakoli M, Shabanzadeh A, Roohbakhsh A, Pourshanazari A. Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats. Basic Clin Pharmacol Toxicol. 2007;101(5):309–314
  182. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, et al. Genetic determinants of response to warfarin during initial anticoagulation. New Engl J Med. 2008;358(10):999–1008
  183. Shurin SB, Nabel EG. Pharmacogenomics – ready for prime time?. New Engl J Med. 2008;358(10):1061–1063

PII: S0268-960X(08)00054-4

doi: 10.1016/j.blre.2008.07.001

Blood Reviews
Volume 23, Issue 2 , Pages 67-78 , March 2009

Article Tools

* Image Usage & Resolution